The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited

BACKGROUND: To compare a near decade of follow-up, newer control cohort data, use of both the societal and third party insurer cost perspectives, and integration of unilateral/bilateral therapy on the comparative effectiveness and cost-effectiveness of intravitreal ranibizumab therapy for neovascula...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Gary C., Brown, Melissa M., Lieske, Heidi B., Turpcu, Adam, Rajput, Yamina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5304393/
https://www.ncbi.nlm.nih.gov/pubmed/28289548
http://dx.doi.org/10.1186/s40942-016-0058-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5304393/
https://www.ncbi.nlm.nih.gov/pubmed/28289548
http://dx.doi.org/10.1186/s40942-016-0058-3

Ejemplares similares